8-K: Charles & Colvard Announces Delisting from Nasdaq Due to Non-Compliance with Filing Requirements

Charles & Colvard will be delisted from the Nasdaq Stock Market due to its failure to timely file its Forms 10-Q for the quarters ended September 30 and December 31, 2024.

Summary

• Charles & Colvard, Ltd. has received a notification from Nasdaq regarding its non-compliance with Listing Rule 5250(c)(1).
• The company failed to timely file its Forms 10-Q for the quarters ended September 30 and December 31, 2024.
• As a result, trading of the company's common stock will be suspended from the Nasdaq Capital Market at the opening of business on April 25, 2025.
• Nasdaq will file a Form 25-NSE with the SEC to remove the company's securities from listing and registration on Nasdaq.
• The company expects that its common stock will be quoted on the OTC Experts Market under the symbol CTHR.
• Charles & Colvard does not intend to appeal Nasdaq's determination, citing the potential for limiting significant costs associated with remaining listed on Nasdaq.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting from Nasdaq, which raises concerns about the company's financial health and compliance.

Positives

• The company is aiming to limit the significant costs associated with remaining listed on Nasdaq by not appealing the delisting decision.

Negatives

• Charles & Colvard is being delisted from Nasdaq, which could negatively impact investor confidence and stock liquidity.
• The company failed to meet Nasdaq's filing requirements, indicating potential issues with internal controls or financial reporting processes.

Risks

• There is no assurance that the company's common stock will continue to trade on the OTC Experts Market.
• There is no guarantee that broker-dealers will continue to provide public quotes of its common stock on the OTC Experts Market.
• The trading volume on the OTC Experts Market may not be sufficient to provide for an efficient trading market.
• The company's strategic plan may not succeed.

Future Outlook

The company expects its common stock to be quoted on the OTC Experts Market following the delisting from Nasdaq, but there are no assurances that a trading market will be maintained.

Management Comments

• The company does not intend to request a hearing to appeal the delisting determination.
• This decision was based on a careful review of numerous factors, including the potential for limiting the significant costs associated with remaining listed on Nasdaq and complying with Nasdaq listing standards.

Industry Context

Delisting from a major exchange like Nasdaq can impact a company's visibility and access to capital, potentially affecting its competitive position within the fine jewelry industry. Other companies in the lab-grown diamond and moissanite space, such as Diamond Foundry and Ada Diamonds, may benefit from Charles & Colvard's reduced visibility.

Comparison to Industry Standards

• Companies like Brilliant Earth (BRLT) maintain their Nasdaq listing by adhering to SEC filing deadlines, setting a benchmark for compliance in the industry.
• Other companies in the jewelry sector, such as Signet Jewelers (SIG), a much larger company, are compared to Charles & Colvard in terms of market capitalization and revenue, highlighting the difference in scale and resources available for compliance.

Stakeholder Impact

• Shareholders may experience a decrease in the value and liquidity of their shares.
• Employees may face uncertainty regarding their job security.
• Customers may have concerns about the company's long-term viability.
• Suppliers may be affected by potential changes in the company's operations.
• Creditors may reassess the company's creditworthiness.

Key Dates

Keywords

delisting, Nasdaq, Form 10-Q, non-compliance, OTC Experts Market, CTHR, Charles & Colvard, filing requirements